## Donald R Royall

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/705730/publications.pdf

Version: 2024-02-01

133 papers 8,026 citations

36 h-index 83 g-index

140 all docs

140 docs citations

140 times ranked

10572 citing authors

#	Article	IF	Citations
1	Cognitive intraindividual variability as a biomarker for functional declines in the Texas Alzheimer's Research and Care Consortium (TARCC) Longitudinal Hispanic Cohort. Alzheimer's and Dementia, 2021, 17, .	0.4	0
2	Serum Adiponectin is Related to Dementia. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 779-783.	1.7	7
3	Β-Related Biomarkers Attenuate Multiple Alzheimer's Disease Conversion Risks and Offer Targets for Intervention. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 2177-2183.	1.7	6
4	Blood-based protein mediators of senility with replications across biofluids and cohorts. Brain Communications, 2020, 2, fcz036.	1.5	11
5	δ scores predict multiple neuropsychiatric symptoms. International Journal of Geriatric Psychiatry, 2020, 35, 1341-1348.	1.3	5
6	δ Scores Identify Subsets of "Mild Cognitive Impairment―with Variable Conversion Risks. Journal of Alzheimer's Disease, 2019, 70, 199-210.	1.2	6
7	Comment on Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia. Journal of the American Geriatrics Society, 2019, 67, 1098-1099.	1.3	0
8	A δHomolog for Dementia Case Finding with Replication in the Alzheimer's Disease Neuroimaging Initiative. Journal of Alzheimer's Disease, 2019, 67, 67-79.	1.2	8
9	Selection for depression-specific dementia cases with replication in two cohorts. PLoS ONE, 2019, 14, e0216413.	1.1	7
10	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
11	FRAILTY MEDIATES SENILITY IN MEXICAN AMERICANS. Innovation in Aging, 2019, 3, S291-S291.	0.0	0
12	Î' PREDICTS GENERAL PSYCHOPATHOLOGY. Innovation in Aging, 2019, 3, S639-S639.	0.0	0
13	Comment on Andrews et al Alzheimer Disease and Associated Disorders, 2019, Publish Ahead of Print, .	0.6	0
14	Bloodâ€based protein predictors of dementia severity as measured by δ: Replication across biofluids and cohorts. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 763-774.	1.2	2
15	Odorant Item Specific Olfactory Identification Deficit May Differentiate Alzheimer Disease From Aging. American Journal of Geriatric Psychiatry, 2018, 26, 835-846.	0.6	26
16	Construction of a Potential Telephone Assessment of Dementia Prevalence and Severity. Journal of Neuropsychiatry and Clinical Neurosciences, 2018, 30, 202-207.	0.9	4
17	P2â€287: A δ HOMOLOG FOR DEMENTIA CASE FINDING WITH REPLICATION IN ADNI. Alzheimer's and Dementia, 2018, 14, P790.	0.4	O
18	O2â€11â€06: BLOODâ€BASED PROTEIN PREDICTORS OF DEMENTIA SEVERITY AS MEASURED BY Î: REPLICATION ACROSS BIOFLUIDS AND COHORTS. Alzheimer's and Dementia, 2018, 14, P649.	0.4	1

#	Article	IF	Citations
19	Serum Adiponectin is Related to Dementia. American Journal of Geriatric Psychiatry, 2018, 26, S94.	0.6	1
20	Executive Interview., 2018, , 1355-1363.		0
21	Exportation and Validation of Latent Constructs for Dementia Case Finding in a Mexican American Population–based Cohort. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2017, 72, gbw004.	2.4	4
22	$\hat{l}'$ scores predict mild cognitive impairment and Alzheimer's disease conversions from nondemented states. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 214-221.	1.2	13
23	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
24	Clock Copying Predicts Mortality in Adult Protective Services Clients. American Journal of Geriatric Psychiatry, 2017, 25, 1012-1016.	0.6	1
25	Cross-Ethnic Differences in the Severity of Neuropsychiatric Symptoms in Persons With Mild Cognitive Impairment and Alzheimer's Disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2017, 29, 13-21.	0.9	30
26	[P3â€"246]: SERUM S100B MEDIATES DEPRESSION's EFFECT ON COGNITION. Alzheimer's and Dementia, 2017, 13, P1035.	0.4	0
27	Few serum proteins mediate APOE's association with dementia. PLoS ONE, 2017, 12, e0172268.	1.1	18
28	Serum proteins mediate depression's association with dementia. PLoS ONE, 2017, 12, e0175790.	1.1	21
29	Executive Interview., 2017, , 1-9.		0
30	Serum protein mediators of dementia and aging proper. Aging, 2016, 8, 3241-3254.	1.4	13
31	P2-057: Amphiregulin Mediates Apoe's Association with Dementia, and Ethnicity Moderates Both Associations. , 2016, 12, P629-P630.		0
32	Thrombopoietin is associated with Î's intercept, and only in Nonâ€Hispanic Whites. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 3, 35-42.	1.2	18
33	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	4.1	260
34	Aging is a weak but relentless determinant of dementia severity. Oncotarget, 2016, 7, 13307-13318.	0.8	3
35	Greater than the sum of its parts: δImproves upon a battery's diagnostic performance Neuropsychology, 2015, 29, 683-692.	1.0	16
36	Welcome Back to Your Future: The Assessment of Dementia by the Latent Variable "δ― Journal of Alzheimer's Disease, 2015, 49, 515-519.	1.2	3

#	Article	IF	Citations
37	δScores are Exportable Across Cultural andÂLinguistic Boundaries. Journal of Alzheimer's Disease, 2015, 49, 561-570.	1.2	6
38	Serum Interleukin (IL)-15 as a Biomarker of Alzheimer's Disease. PLoS ONE, 2015, 10, e0117282.	1.1	43
39	Future Dementia Severity is Almost Entirely Explained by the Latent Variable Î''s Intercept and Slope. Journal of Alzheimer's Disease, 2015, 49, 521-529.	1.2	23
40	Greater than the Sum of Its Parts: $\hat{l}$ can be Constructed from Item Level Data. Journal of Alzheimer's Disease, 2015, 49, 571-579.	1.2	11
41	Serum IGF-BP2 strongly moderates age's effect on cognition: a MIMIC analysis. Neurobiology of Aging, 2015, 36, 2232-2240.	1.5	10
42	Neuropsychiatric symptoms in community-dwelling Mexican-Americans: results from the Hispanic Established Population for Epidemiological Study of the Elderly (HEPESE) study. International Journal of Geriatric Psychiatry, 2015, 30, 300-307.	1.3	19
43	$\tilde{A}$ ¢â,¬Å"Executive functions $\tilde{A}$ ¢â,¬Â•cannot be distinguished from general intelligence: two variations on a single theme within a symphony of latent variance. Frontiers in Behavioral Neuroscience, 2014, 8, 369.	1.0	25
44	The Temporospatial Evolution of Neuritic Plaque-Related and Independent Tauopathies: Implications for Dementia Staging. Journal of Alzheimer's Disease, 2014, 40, 541-549.	1.2	10
45	Ethnicity Moderates Dementia's Biomarkers. Journal of Alzheimer's Disease, 2014, 43, 275-287.	1.2	24
46	Telephone Screening for Mild Cognitive Impairment in Hispanics Using the Alzheimer's Questionnaire. Experimental Aging Research, 2014, 40, 129-139.	0.6	13
47	Latent variables may be useful in pain's assessment. Health and Quality of Life Outcomes, 2014, 12, 13.	1.0	6
48	Towards an Aging-Specific Cognitive Phenotype: The Freedom House Study. Experimental Aging Research, 2014, 40, 245-265.	0.6	9
49	Vitamin D Binding Protein as a Serum Biomarker of Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 43, 37-45.	1.2	28
50	Does ethnicity moderate dementia's biomarkers?. Neurobiology of Aging, 2014, 35, 336-344.	1.5	16
51	Neuropsychological Correlates of Performance Based Functional Status in Elder Adult Protective Services Referrals for Capacity Assessments. Journal of Elder Abuse and Neglect, 2013, 25, 294-304.	0.5	8
52	Fortress Brain. Medical Hypotheses, 2013, 80, 118-121.	0.8	1
53	Alzheimer's disease pathology does not mediate the association between depressive symptoms and subsequent cognitive decline. Alzheimer's and Dementia, 2013, 9, 318-325.	0.4	43
54	Risk factors for mild cognitive impairment among Mexican Americans. Alzheimer's and Dementia, 2013, 9, 622.	0.4	79

#	Article	IF	Citations
55	Validation of a Latent Construct for Dementia Case-Finding in Mexican-Americans. Journal of Alzheimer's Disease, 2013, 37, 89-97.	1.2	18
56	The Default Mode Network may be the Key Substrate of Depressive Symptom-Related Cognitive Changes. Journal of Alzheimer's Disease, 2013, 34, 547-560.	1.2	22
57	Getting Past "g― Testing a New Model of Dementing Processes in Persons Without Dementia. Journal of Neuropsychiatry and Clinical Neurosciences, 2012, 24, 37-46.	0.9	25
58	The Default Mode Network and Related Right Hemisphere Structures may be the Key Substrates of Dementia. Journal of Alzheimer's Disease, 2012, 32, 467-478.	1.2	35
59	Validation of a Latent Variable Representing the Dementing Process. Journal of Alzheimer's Disease, 2012, 30, 639-649.	1.2	45
60	Modeling regional vulnerability to Alzheimer pathology. Neurobiology of Aging, 2012, 33, 1556-1563.	1.5	11
61	Estimating the Temporal Evolution of Alzheimer's Disease Pathology with Autopsy Data. Journal of Alzheimer's Disease, 2012, 32, 23-32.	1.2	5
62	Depressive symptoms predict longitudinal change in executive control but not memory. International Journal of Geriatric Psychiatry, 2012, 27, 89-96.	1.3	36
63	THE QUEST FOR BIOMARKERS OF ALZHEIMER'S DISEASE. Journal of the American Geriatrics Society, 2011, 59, 377-378.	1.3	0
64	Metaâ€analysis of <sup>123</sup> lâ€MIBG cardiac scintigraphy for the diagnosis of Lewy body–related disorders. Movement Disorders, 2011, 26, 1218-1224.	2.2	92
65	Reply to Treglia et al.: <sup>123</sup> lâ€metaiodobenzylguanidine cardiac scintigraphy appears feasible despite proposed obstacles. Movement Disorders, 2011, 26, 1950-1950.	2.2	0
66	Executive Interview., 2011,, 992-997.		1
67	Missing Data? Plan on It!. Journal of the American Geriatrics Society, 2010, 58, S343-8.	1.3	33
68	Randomized, Placebo-Controlled, Clinical Trial of Donepezil in Vascular Dementia. Stroke, 2010, 41, 1213-1221.	1.0	138
69	VISUOSPATIAL IMPAIRMENT AND MORTALITY. Journal of the American Geriatrics Society, 2009, 57, 932-933.	1.3	1
70	Executive Function in Self-Neglecting Adult Protective Services Referrals Compared With Elder Psychiatric Outpatients. American Journal of Geriatric Psychiatry, 2009, 17, 907-910.	0.6	29
71	Asymmetric Insular Function Predicts Positional Blood Pressure in Nondemented Elderly. Journal of Neuropsychiatry and Clinical Neurosciences, 2009, 21, 173-180.	0.9	3
72	Sertraline Improves Executive Function in Patients With Vascular Cognitive Impairment. Journal of Neuropsychiatry and Clinical Neurosciences, 2009, 21, 445-454.	0.9	20

#	Article	IF	CITATIONS
73	Clockâ€drawing potentially mediates the effect of depression on mortality: replication in three cohorts. International Journal of Geriatric Psychiatry, 2008, 23, 821-829.	1.3	13
74	In Regard to Fuller et al International Journal of Radiation Oncology Biology Physics, 2008, 72, 301.	0.4	1
75	Measurement of meaningful treatment effects in CADASIL. Lancet Neurology, The, 2008, 7, 673-674.	4.9	1
76	SLIPPERY SLOPES. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2008, 63, 107-107.	1.7	0
77	Depression, Disability and Intermediate Pathways: A Review of Longitudinal Studies in Elders. Journal of Geriatric Psychiatry and Neurology, 2008, 21, 183-197.	1.2	88
78	Insular Alzheimer disease pathology and the psychometric correlates of mortality Cleveland Clinic Journal of Medicine, 2008, 75, S97-S97.	0.6	26
79	The Cognitive Correlates of Functional Status: A Review From the Committee on Research of the American Neuropsychiatric Association. Journal of Neuropsychiatry and Clinical Neurosciences, 2007, 19, 249-265.	0.9	303
80	Clock Drawing Phenotypes in Community-Dwelling African Americans and Caucasians: Results from the University of Alabama at Birmingham Study of Aging. Neuroepidemiology, 2007, 28, 175-180.	1.1	13
81	Efficacy and Safety of Galantamine in Patients with Dementia with Lewy Bodies: A 24-Week Open-Label Study. Dementia and Geriatric Cognitive Disorders, 2007, 23, 401-405.	0.7	82
82	Location, location, location!. Neurobiology of Aging, 2007, 28, 1481-1482.	1.5	15
83	Depression and Mortality in Elders Referred for Geriatric Psychiatry Consultation. Journal of the American Medical Directors Association, 2007, 8, 318-321.	1.2	19
84	Cognitive Predictors of Mortality in Elderly Retirees: Results From the Freedom House Study. American Journal of Geriatric Psychiatry, 2007, 15, 243-251.	0.6	23
85	Executive Function and Capacity to Consent to a Noninvasive Research Protocol. American Journal of Geriatric Psychiatry, 2007, 15, 159-162.	0.6	25
86	Insular Alzheimer's disease pathology as a cause of "age-related―autonomic dysfunction and mortality in the non-demented elderly. Medical Hypotheses, 2006, 67, 747-758.	0.8	50
87	Mexican-American Ethnicity and Cognitive Function: Findings from an Elderly Southwestern Sample. Journal of Neuropsychiatry and Clinical Neurosciences, 2006, 18, 350-355.	0.9	14
88	Mild Cognitive Impairment and Functional Status. Journal of the American Geriatrics Society, 2006, 54, 163-165.	1.3	23
89	Double Jeopardy. Chest, 2006, 130, 1636-1638.	0.4	13
90	Normal rates of cognitive change in successful aging: The Freedom House Study. Journal of the International Neuropsychological Society, 2005, 11, 899-909.	1.2	94

#	Article	IF	CITATIONS
91	Executive Control Mediates Memory's Association with Change in Instrumental Activities of Daily Living: The Freedom House Study. Journal of the American Geriatrics Society, 2005, 53, 11-17.	1.3	141
92	An Empiric Approach to Level of Care Determinations: The Importance of Executive Measures. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2005, 60, 1059-1064.	1.7	39
93	Prevalence, Course, and Risk Factors for Executive Impairment in Patients Hospitalized on a General Medicine Service. Psychosomatics, 2005, 46, 411-417.	2.5	26
94	The Impact of Medical Illness on Executive Function. Psychosomatics, 2005, 46, 508-516.	2.5	71
95	Amplification of Herpes simplex type 1 and Human Herpes type 5 viral DNA from formalin-fixed Alzheimer brain tissue. Neuroscience Letters, 2005, 390, 37-41.	1.0	9
96	Feasibility of Quantifying the Effects of Epoetin Alfa Therapy on Cognitive Function in Women with Breast Cancer Undergoing Adjuvant or Neoadjuvant Chemotherapy. Clinical Breast Cancer, 2005, 5, 439-446.	1.1	110
97	Misclassification Is Likely in the Assessment of Mild Cognitive Impairment. Neuroepidemiology, 2004, 23, 185-191.	1.1	45
98	Declining Executive Control in Normal Aging Predicts Change in Functional Status: The Freedom House Study. Journal of the American Geriatrics Society, 2004, 52, 346-352.	1.3	294
99	The "Subsyndromal―Syndromes of Aging. Journal of the American Geriatrics Society, 2004, 52, 463-	46.5.	4
100	A diagnostic dilemma: is "Alzheimer's dementia―Alzheimer's disease, vascular dementia, or both?. Lancet Neurology, The, 2004, 3, 141.	4.9	35
101	Executive control and the validity of survey data. International Journal of Geriatric Psychiatry, 2004, 19, 696-698.	1.3	5
102	Prevalence and patterns of executive impairment in community dwelling Mexican Americans: results from the Hispanic EPESE Study. International Journal of Geriatric Psychiatry, 2004, 19, 926-934.	1.3	32
103	Vascular cognitive disorder: a new diagnostic category updating vascular cognitive impairment and vascular dementia. Journal of the Neurological Sciences, 2004, 226, 81-87.	0.3	242
104	I wish to commend De Jager et al. (2003) for their study of neuropsychological measures in Alzheimer's disease (AD), vascular dementia (VaD) and Mild Cognitive Impairment (MCI). Psychological Medicine, 2004, 34, 761-762.	2.7	3
105	Executive dyscontrol in normal aging: Normative data, factor structure, and clinical correlates.  Current Neurology and Neuroscience Reports, 2003, 3, 487-493.	2.0	20
106	Validation of a Spanish translation of the CLOX for use in Hispanic samples: the Hispanic EPESE study. International Journal of Geriatric Psychiatry, 2003, 18, 135-141.	1.3	42
107	The $\tilde{A} \in \hat{A} \in \hat{A}$ $\otimes A$ lzheimerization $\tilde{A} \in \hat{A} \in \hat{A}$ of Dementia Research. Journal of the American Geriatrics Society, 2003, 51, 277-278.	1.3	32
108	Prevalence of Executive Impairment in Patients Seen by a Psychiatry Consultation Service. Psychosomatics, 2003, 44, 290-297.	2.5	29

#	Article	IF	Citations
109	Decline in Learning Ability Best Predicts Future Dementia Type: The Freedom House Study. Experimental Aging Research, 2003, 29, 385-406.	0.6	19
110	Aging, Overview., 2003,, 53-57.		2
111	Executive Control Function. Journal of Neuropsychiatry and Clinical Neurosciences, 2002, 14, 377-405.	0.9	455
112	Severe Dysosmia Is Specifically Associated with Alzheimer-Like Memory Deficits in Nondemented Elderly Retirees. Neuroepidemiology, 2002, 21, 68-73.	1.1	71
113	Alzheimer Disease as a Vascular Disorder: Nosological Evidence. Stroke, 2002, 33, 2147-2148.	1.0	14
114	Pathological Determinants of the Transition to Clinical Dementia in Alzheimer's Disease. Experimental Aging Research, 2002, 28, 143-162.	0.6	93
115	Geriatric Depression and Chronic Medical Disease: Another World of Hurt. Journal of the American Geriatrics Society, 2002, 50, 969-970.	1.3	5
116	NOT ALL CLOCK-DRAWING TASKS ARE THE SAME. Journal of the American Geriatrics Society, 2002, 50, 1166-1167.	1.3	13
117	Back to the Future of Mental Capacity Assessment. Journal of the American Geriatrics Society, 2002, 50, 1884-1885.	1.3	9
118	The FAB: A frontal assessment battery at bedside. Neurology, 2001, 57, 565-565.	1.5	26
119	Frontal MRI Findings Associated with Impairment on the Executive Interview (EXIT25). Experimental Aging Research, 2001, 27, 293-308.	0.6	38
120	Executive Cognitive Impairment: A Novel Perspective on Dementia. Neuroepidemiology, 2000, 19, 293-299.	1.1	103
121	The Use of Herbal Alternative Medicines in Neuropsychiatry. Journal of Neuropsychiatry and Clinical Neurosciences, 2000, 12, 177-192.	0.9	18
122	Frontal systems impairment in major depression. Seminars in Clinical Neuropsychiatry, 1999, 4, 13-23.	1.9	28
123	Neuropsychiatric Correlates and Treatment of Lenticulostriatal Diseases. Journal of Neuropsychiatry and Clinical Neurosciences, 1998, 10, 249-266.	0.9	109
124	Executive Dyscontrol: An Important Factor Affecting the Level of Care Received by Older Retirees. Journal of the American Geriatrics Society, 1998, 46, 1519-1524.	1.3	85
125	Dementias That Present With and Without Posterior Cortical Features: An Important Clinical Distinction. Journal of the American Geriatrics Society, 1998, 46, 98-105.	1.3	43
126	Executive Control and the Comprehension of Medical Information by Elderly Retirees. Experimental Aging Research, 1997, 23, 301-313.	0.6	80

#	Article	IF	CITATIONS
127	COMMENTS ON THE EXECUTIVE CONTROL OF CLOCKâ€DRAWING. Journal of the American Geriatrics Society, 1996, 44, 218-219.	1.3	15
128	VALIDATING THE GDS IN A NURSING HOME SAMPLE. Journal of the American Geriatrics Society, 1996, 44, 98-99.	1.3	7
129	Precis of executive dyscontrol as a cause of problem behavior in dementia. Experimental Aging Research, 1994, 20, 73-94.	0.6	59
130	Bedside assessment of frontal degeneration: Distinguishing alzheimer's disease from non-alzheimer's cortical dementia. Experimental Aging Research, 1994, 20, 95-103.	0.6	51
131	Bedside Assessment of Executive Cognitive Impairment: The Executive Interview. Journal of the American Geriatrics Society, 1992, 40, 1221-1226.	1.3	523
132	ECF Deficits and Anorectic Behavior. Journal of the American Geriatrics Society, 1991, 39, 840-841.	1.3	1
133	Frontal MRI Findings Associated with Impairment on the Executive Interview (EXIT25). , 0, .		8